Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.73 |
| ▸ | RXRB | P28702 | 9/20 | 0.73 |
| ▸ | RXRG | P48443 | 9/20 | 0.73 |
| ▸ | RARB | P10826 | 5/20 | 0.73 |
| ▸ | RARG | P13631 | 4/20 | 0.73 |
| ▸ | RARA | P10276 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
| ▸ | PGR | P06401 | 1/20 | 0.73 |
| ▸ | HTR1A | P08908 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | DRD1 | P21728 | 1/20 | 0.73 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31758293 | 1.00 | RXRA (0.73) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL24055389 | 0.95 | RXRA (0.67) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7897711 | 0.90 | RXRA (0.63) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL20315197 | 0.89 | RXRA (0.73) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL16926945 | 0.88 | RXRA (0.64) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL20805523 | 0.88 | RXRA (0.71) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL16926727 | 0.87 | RXRA (0.60) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6890269 | 0.87 | RXRA (0.70) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL20398869 | 0.86 | RXRA (0.62) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL3982018 | 0.86 | RXRA (0.72) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008740-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DJ Therapeutics LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12338214-B2 | Bexarotene derivatives and their use in treating cancer | DJ Therapeutics LLC (US) | 2025-06-24 | — | — | US | disclosed |
| CN-113233980-B | Synthesis method of beta-chloroacid ester and alpha, beta-unsaturated acid ester compound | 台州学院 | 2022-04-05 | — | — | CN | disclosed |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DAWN SCIENTIFIC PHARMACEUTICALS, LLC | 2021-11-25 | — | — | US | disclosed |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DAWN SCIENTIFIC PHARMACEUTICALS, LLC | 2021-11-25 | — | — | US | disclosed |
| CN-113233980-A | Synthesis method of beta-chloroacid ester and alpha, beta-unsaturated acid ester compound | 台州学院 | 2021-08-10 | — | — | CN | disclosed |
| EP-3758694-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | DJ Therapeutics LLC (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-2536276-B1 | NOVEL BEXAROTENE ANALOGS | UNIV ARIZONA (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9174917-B2 | Bexarotene analogs | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174917-B2 | Bexarotene analogs | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20120309833-A1 | NOVEL BEXAROTENE ANALOGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2012-12-06 | — | — | US | disclosed |
| US-20120309833-A1 | NOVEL BEXAROTENE ANALOGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2012-12-06 | — | — | US | disclosed |
| WO-2011141928-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE BEXAROTENE | IND-SWIFT LABORATORIES LIMITED (IN) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011103321-A1 | NOVEL BEXAROTENE ANALOGS | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2011-08-25 | — | — | WO | disclosed |
| US-5837725-A | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors | SRI INTERNATIONAL (US) | 1998-11-17 | — | — | US | disclosed |
| US-5466861-A | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors | SRI INTERNATIONAL (US) | 1995-11-14 | — | — | US | disclosed |
| EP-0671005-A1 | RXR HOMODIMER FORMATION AND BRIDGED BICYCLIC AROMATIC COMPOUNDS AND THEIR USE IN MODULATING GENE EXPRESSION | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994012880-A2 | RXR HOMODIMER FORMATION AND BRIDGED BICYCLIC AROMATIC COMPOUNDS AND THEIR USE IN MODULATING GENE EXPRESSION | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338214-B2 | Bexarotene derivatives and their use in treating cancer | C3AR1, CXCR3, CCR7 | RXRA 9/4885RXRB 18/4885RXRG 8/4885 |
| US-20210363093-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | ENPP2, XPA, CCR8 | RXRA 4/4885RXRB 13/4885RXRG 5/4885 |
| US-20260008740-A1 | BEXAROTENE DERIVATIVES AND THEIR USE IN TREATING CANCER | CXCR3, CCR6, CCR9 | RXRA 63/4885RXRB 76/4885RXRG 69/4885 |
| US-20120309833-A1 | NOVEL BEXAROTENE ANALOGS | TBXA2R, ENPP2, CXCL8 | RXRA 14/4885RXRB 7/4885RXRG 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.